Skip to content

The clinical research of Ulinastatin injection modifying vascular permeability in sepsis patients by regulating endothelial cell glycocalyx and its mechanism.

The clinical research of Ulinastatin injection modifying vascular permeability in sepsis patients by regulating endothelial cell glycocalyx and its mechanism.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-16007732
Enrollment
Unknown
Registered
2016-01-09
Start date
2016-01-11
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sepsis

Interventions

Control group:Saline

Sponsors

The Third Affiliated Hospital of Third Military Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. The target patients are supposed to have been given a confirmed diagnosis of clinical sepsis(sepsis3.0); 2. The target patients are supposed to be using PICOO (pulse indicator continuous cardiac output) or noninvasive hemodynamic monitoring; 3. The target patients are supposed to have signed medical informed consent.

Exclusion criteria

Exclusion criteria: 1. aged less than 18 or more than 80; 2. Primary with left heart failure; 3. suffering from disease of immune system or severe hypoimmunity.using hormones, immunosuppressor or immune conditioning therapy within a month; 4. having used ulinastatin treatment; 5. with a primary disease of low serum protein or chemotherapy, cancer, pregnancy; 6. unable to complete deep vein catheterization and related treatment because of other reasons.

Design outcomes

Primary

MeasureTime frame
Pulmonary Vascular Permeability Index;heparan sulfate;

Countries

China

Contacts

Public ContactJifu Qu
1284590786@qq.com+86 13896099633

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026